Article Text
Abstract
Background: In 1998, highly active antiretroviral therapy (HAART) was widespread, but the diffusion of these life-saving treatments was not uniform. As half of all AIDS patients in the USA have Medicaid coverage, this study of a multistate Medicaid claims dataset was undertaken to assess disparities in the rates of HAART.
Methods: Data came from 1998 Medicaid claims files from five states with varying HIV prevalence. ICD-9 codes were used to identify people with a diagnosis of HIV/AIDS or AIDS-defining illness. Multivariate analyses assessed associations between age, gender, race and state of residence for antiretroviral regimens consistent with HAART, as defined by 1998 Centers for Disease Control and Prevention (CDC) guidelines.
Results: Among 7202 Medicaid enrolees with a diagnosis of HIV/AIDS or AIDS, 62% received HAART and 25% received no antiretroviral therapy. Multivariate analyses showed that age, race, gender and state were all significant predictors of receiving HAART: white, non-Hispanic patients were most likely to receive HAART (68.3%), with lower rates in Hispanic and black, non-Hispanic segments of the population (59.3% and 57.5%, respectively, p<0.001). Women were less likely to receive HAART than men (51.8% vs 69.3%, p<0.001).
Conclusion: Despite similar insurance coverage and drug benefits, life-saving treatments for HIV/AIDS diffused at widely varying rates in different segments of the Medicaid population. Research is needed to determine the extent to which racial, gender, interstate and region disparities currently correspond to barriers to such care.
Statistics from Altmetric.com
Footnotes
Funding: WDK was a postdoctoral fellow at UCLA CARE Center within the Department of Infectious Diseases and sponsored by Adult AIDS Clinical Trials Group Minority AIDS Training Program. He was partially supported by National Institute of Drug Abuse U01DA17394 and UCLA/DREW Project Export, NCMHD P20MD000148/P20MD000182.
Competing interests: None declared.
Ethics approval: IRB approval from the Morehouse School of Medicine and IRB exemption from the University of California.
Linked Articles
- In this issue